MedPath

ZetaGen Therapeutics, Inc.

ZetaGen Therapeutics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2015-01-01
Employees
11
Market Cap
-
Website
http://www.zetagen.com

Clinical Trials

2

Active:1
Completed:0

Trial Phases

2 Phases

Phase 2:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (50.0%)
Phase 2
1 (50.0%)

Pilot Study of ZetaFuse™ Bone Graft for the Treatment of Cervical Degenerative Disc Disease

Not Applicable
Recruiting
Conditions
Myelopathy Cervical
Disc Disease
Disc Degeneration
Neurological Abnormality
Radiculopathy, Cervical
First Posted Date
2023-08-02
Last Posted Date
2025-04-24
Lead Sponsor
Zetagen Therapeutics, Inc
Target Recruit Count
10
Registration Number
NCT05971329
Locations
🇦🇺

Prince of Wales Private Hospital, Randwick, New South Wales, Australia

🇦🇺

Prince of Wales Public Hospital, Randwick, New South Wales, Australia

ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONES

Phase 2
Active, not recruiting
Conditions
Metastatic Breast Cancer in the Spine
First Posted Date
2022-03-15
Last Posted Date
2025-07-20
Lead Sponsor
Zetagen Therapeutics, Inc
Target Recruit Count
10
Registration Number
NCT05280067
Locations
🇨🇦

Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada

🇨🇦

McGill University Health Center, Montréal, Quebec, Canada

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.